As doctors received more money from the company that sells an expensive drug known as Acthar Gel, the number of prescriptions written climbed and Medicare spending rose substantially, suggesting the payments swayed medical practice and cost taxpayers a bundle, according to a new analysis.

Specifically, for every $10,000 that Mallinckrodt (MNK) paid physicians in 2015, Medicare spending rose by 7.9 percent, or $53,000, for the drug, which is used to treat infantile spasms but often prescribed for more than a dozen other maladies as well. All totaled, Medicare spent more than $500 million on the drug that year. The analysis, which appeared in the JAMA Network Open, examined payments to three types of specialists: nephrologists, neurologists, and rheumatologists.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The company way not ‘have it backwards’ – “They rationalize the high price, because they’re using all that revenue to do the research to fill in the evidence gaps.” But, allowing for inflation the 1990 price should be about $41 USD. Now the remaining 99.998 % of the increase is “because they can.”

Your daily dose of news in health and medicine

Privacy Policy